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Background Clinical trials evaluating the effect of calcium supplementation on bone loss in 2 
lactating women were small and results are inconsistent. 3 
Objective To determine the effect of calcium supplementation on bone mineral density (BMD) 4 
in lactating women. 5 
Design Electronic search of databases was conducted from inception to January 2020. Two 6 
authors screened studies, extracted data and assessed the risk of bias of eligible studies. 7 
Percentage change in BMD was pooled using random-effects models and reported as weighted 8 
mean differences (WMD) with 95% confidence intervals (CI). Risk of bias was assessed using 9 
the Cochrane risk of bias tool. 10 
Results Five randomized controlled trials including 567 lactating women were included. All 11 
had a high risk of bias. Mean baseline calcium intake ranged from 562 to 1333 mg/day. 12 
Compared to control groups (placebo/no intervention), calcium supplementation (600/1000 13 
mg/day) had no significant effect on BMD at the lumbar spine (WMD=0.74% [95% CI -0.10, 14 
1.59]; I2=47% [95% CI 0, 81], n=527 from 5 trials) or the forearm (WMD=0.53% [95% CI -15 
0.35, 1.42%]; I2=55% [95% CI 0, 85], n=415 from 4 trials). BMD at other sites was assessed 16 
in single trials: calcium supplementation had a small to moderate effect on total hip BMD 17 
(WMD=3.3% [95% CI 1.5, 5.1]) but no effect on total body or femoral neck BMD.  18 
Conclusions Overall, the meta-analysis indicates that calcium supplementation does not 19 
provide clinically important benefits for BMD in lactating women. However, there was 20 
adequate dietary intake before supplementation in some studies, and others did not measure 21 
baseline calcium intake. Advising lactating women to meet the current recommended calcium 22 





evidence to the contrary from robust clinical trials becomes available. More research needs to 24 
be done in larger samples of women from diverse ethnic and racial groups.  25 
 26 
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Low bone mineral density (BMD) is a major risk factor for osteoporotic fracture in the elderly 30 
(1, 2). BMD in later life is determined by both peak bone mass and the rate of subsequent bone 31 
loss (3). The higher the peak bone mass that is achieved by the early 20s, the greater the 32 
likelihood of withstanding the impacts of age-related bone loss (4). Therefore, optimizing 33 
BMD in young adulthood is critically important for preventing fractures in later life. 34 
Numerous studies have demonstrated a remarkable bone loss in lactating women (5-8), which 35 
is likely due to increased bone resorption to meet the high calcium requirement of their infants. 36 
Moreover, there is some evidence that a longer duration of lactation could be associated with 37 
a reduction of BMD after 6 months post-weaning (9, 10), although this is not seen in all studies 38 
(11-13). Nevertheless, preventive strategies for preventing bone loss or even improving bone 39 
density in lactating women are scarce. 40 
Calcium supplementation has potential value for BMD by reducing bone turnover, particularly 41 
in those with marginal and low dietary calcium intake (14, 15). In particular, as an average of 42 
200 mg of calcium per day is secreted by breast-feeding secretes (16), this period could provide 43 
a window of opportunity for younger women to benefit more from calcium supplementation. 44 
However, the recommended dietary allowances for calcium intake for lactating women (17) 45 
(1000/1300 mg/day depending on age) are the same as those for non-lactating women. The 46 
main argument for this is that maternal skeletal resorption is hormonally programmed during 47 
lactation to supply the necessary calcium for breastfeeding and there is no evidence from 48 
randomized controlled trials (RCTs) and observational studies to show that increased calcium 49 
intake could prevent bone loss during lactation (18). However, RCTs examining the effect of 50 
calcium supplementation on BMD in lactating women are generally of small sample size and 51 





has been done to quantitively determine the effect of calcium supplementation on BMD in 53 
lactating women. Thus, this study aimed to address this evidence gap by determining the effect 54 
of calcium supplementation on BMD in lactating women and whether any such effect varies 55 
by baseline calcium intake, dose of calcium supplementation, co-intervention of vitamin D, 56 
duration of supplementation or breast-feeding, age or ethnicity.  57 
 58 
Methods 59 
Protocol registration 60 
The protocol for the systematic review and meta-analysis was registered with PROSPERO 61 
(https://www.crd.york.ac.uk/PROSPERO, ID: CRD42015022092) (24). This study is reported 62 
as per the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 63 
checklist (25). 64 
 65 
Literature search 66 
We searched EMBASE (via Ovid), MEDLINE (via PubMed), Web of Science and Cochrane 67 
Central Register of Controlled Trials (CENTRAL, via The Cochrane Library) from inception 68 
(that is, from the date the database was established) to June 2015 and updated in January 2020 69 
for RCTs of calcium supplementations in lactating women with BMD, total body bone mineral 70 
content (BMC), fracture, quality of life or adverse events as an endpoint. See Supplementary 71 
Method for a detailed search strategy for MEDLINE. We checked bibliographies of original 72 
studies and recent review articles for additional relevant studies. We also searched 73 
ClinicalTrials.gov and the WHO trials portal (www.who.int/ictrp/en/) for clinical trials that 74 






Study selection 77 
Two authors (GC and JT) independently screened titles and abstracts for all identified studies 78 
and retrieved the full text of potentially relevant studies for further screening. Full-text reviews 79 
were performed according to the a priori selection criteria which is detailed in the registered 80 
protocol (24). Briefly, we included studies if they were (a) online published full-text articles or 81 
conference abstracts; (b) written in any language; (c) RCTs evaluating the effect of calcium 82 
supplementations (including calcium fortified food) with or without a co-intervention of 83 
vitamin D for at least 3 months in lactating women who decided to breast-feed their infants for 84 
at least 3 months; (d) aiming at BMD, total body BMC, fractures, quality of life or adverse 85 
events as an outcome measure. If the supplementation started during pregnancy, studies were 86 
included if the duration of supplementation in the postpartum period was at least double of that 87 
in pregnancy. Studies eligible for the systematic review were included in the meta-analysis if 88 
they provided sufficient data for pooling on any outcome measures outlined above. Given that 89 
few placebo-controlled trials (n=3) were available for this review, we amended the protocol to 90 
also include trials that used no intervention as control group rather than only including placebo-91 
controlled trials as originally planned. 92 
 93 
Data extraction 94 
Two authors (GC and FW) independently extracted information from each included study 95 
using a data collection form. Data extracted were: (a) study characteristics (first author, year of 96 
publication, study design, inclusion and exclusion criteria, sample size and duration of follow-97 
up); (b) participants’ characteristics (age, ethnicity and baseline calcium intake); (c) 98 
interventions (dose and duration of calcium supplementation); and (d) outcome measures 99 
(techniques, sites and timing of BMD measurement). Where available, we extracted the 100 





the following sites: total hip, femoral neck, lumbar spine and forearm. As BMD at the forearm 102 
can be measured at different sites (e.g., ultradistal, proximal, distal third of radius), we used 103 
BMD at the most commonly reported site (ultradistal radius) or any other radius site if BMD 104 
at the ultradistal radius was not available. For BMD that was measured at multiple time points, 105 
we extracted data for the time points that were (a) shared by most studies included and (b) at 106 
the end of supplementation. When the outcomes were shown as graphs only, we converted 107 
graphical data to numerical data using Engauge Digitizer software (Version 10.11) (26, 27). 108 
Data on other pre-specified outcomes (i.e., total body BMC, fractures, quality of life and 109 
adverse events) were not extracted as they were not reported in any study. 110 
 111 
Assessment of risk of bias and quality of evidence 112 
Two authors (GC and FW) independently assessed the risk of bias using Cochrane’s risk of 113 
bias assessment (28), with disagreements discussed with a third author (JT). For each outcome, 114 
we assessed quality of evidence using the GRADE (Grading of Recommendations, Assessment, 115 
Development, and Evaluation) approach, which combines risk of bias, consistency of effect, 116 
imprecision, indirectness and publication bias (29). Quality of evidence was downgraded from 117 
high (i.e., RCT) to very low based on the seriousness of each component in the GRADE. The 118 
GRADE Summary of Findings table was generated using GRADEpro Guideline Development 119 
Tool on the GRADEpro website (https://gdt.gradepro.org/app/).  120 
 121 
Data synthesis 122 
No studies reported fractures, quality of life, adverse events or withdrawals due to adverse 123 
events so these could not be analyzed. The most commonly shared time point at which BMD 124 





number of studies, in the main analysis we pooled the data of BMD outcomes at the end of 126 
supplementation from all five studies (i.e. 6 months for 2 studies (20, 22) and 9 (23), 10 (21) 127 
and 18 (19) months for each of the remaining three studies), and we also pooled the data at the 128 
most commonly shared time points (i.e. 3 and 6 months). We calculated the weighted mean 129 
difference (WMD) with 95% confidence intervals (CI) between calcium supplementation and 130 
control groups of the percentage changes of BMD using DerSimonian and Laird random-131 
effects models (30). The pooled results were presented in forest plots. All data syntheses were 132 
carried out with Review Manager software (version 5.3).  133 
 134 
Assessment of heterogeneity 135 
Statistical heterogeneity was assessed using the I2 and Chi-square test. I2 > 50% was considered 136 
substantial heterogeneity and a p-value of ≤ 0.10 in the chi-square test indicated statistical 137 
significance. The 95% CIs of the I2 estimate were calculated based on Higgins et al. (31). 138 
 139 
Assessment of publication bias 140 
As only a limited number of studies were included in this systematic review and meta-analysis, 141 
we used funnel plots only to visually assess publication bias.  142 
  143 
Subgroup analysis 144 
The planned a priori subgroup analyses were not undertaken due to the small number of 145 
included studies. Those planned were by: (a) baseline calcium intake (< or ≥ 1000 mg/day); (b) 146 





or no); (d) duration of supplementation (< or ≥ 12 months); (e) duration of breast-feeding (< or 148 
≥ 6 months); (f) age (< or ≥ 30 years) and; (g) ethnicity.  149 
 150 
 151 
Sensitivity analysis 152 
A priori sensitivity analyses were performed by omitting studies with inappropriate or unclear 153 
allocation concealment and omitting studies that used no intervention as a control group. Given 154 
our inability to explore heterogeneity using subgroup analyses due to the small numbers of 155 
studies, we opted to address heterogeneity instead by performing a post hoc sensitivity analysis 156 
excluding a single study (23) which was markedly different from the remaining studies for a 157 
number of our prespecified subgroup characteristics (32) and using 6-month lactation data only 158 
of an 18-month study (19). In addition, another post hoc sensitivity analysis was conducted by 159 
excluding a study that was published as a conference abstract (20). 160 
 161 
Results 162 
Study selection 163 
The flow chart of the study selection process is detailed in Figure 1. Our electronic search 164 
identified 2871 potentially relevant records. Of these, 634 were excluded as duplicates and 165 
2206 excluded after screening for titles and abstracts. We performed full-text screening of the 166 
remaining 31 references, and five RCTs involving 567 participants (293 in the calcium 167 
supplementation group and 274 in the control group) were included in this review.  168 
Table 1 presents the characteristics of included studies(19-23). Four studies were performed in 169 





age of lactating women ranged from 27.5 to 31 years. The duration of breastfeeding ranged 171 
from 3 to 7.6 months. Of note, one study by Yu et al. started calcium supplementation when 172 
most participants had ceased lactating(23). In another, supplementation occurred both during 173 
lactation (about 6 months) and for 12-months post lactation (19). Mean calcium intake at 174 
baseline was reported in 4 studies and ranged from 562 to 1333 mg/day (20-23). The dose of 175 
calcium supplementation was 1000 mg/day in four trials (19-22) and 600 mg/day in one trial 176 
(23). Two studies provided 400 IU/day vitamin D to both the calcium supplementation and 177 
control groups (21, 22). BMD was measured by dual-energy x-ray absorptiometry (DXA) in 178 
all studies. The longest follow-up times ranged from 6 to 18 months with calcium 179 
supplementation provided during the entire follow-up. All studies compared the percentage 180 
change of BMD (%) from baseline to the end of follow-up between calcium supplementation 181 
group and control group. All studies measured BMD at the lumbar spine and four at the 182 
forearm(19-22) and single studies only reported BMD at whole body (21), total hip (23) and 183 
proximal femur (20). No studies reported total body BMC, fracture, quality of life or adverse 184 
events as outcomes. Two studies reported the mean (standard deviation [SD]) of BMD at 185 
baseline by treatment group. In the Polatti study (19), baseline lumbar spine BMD was 1.239 186 
(0.018) g/cm2 in the calcium supplementation group and 1.220 (0.014) g/cm2 in the control 187 
group, and forearm BMD was 0.469 (0.009) g/cm2 and 0.489 (0.008) g/cm2 in the treatment 188 
and control groups, respectively. In the Yu study (23), lumbar spine BMD was 0.977 (0.099) 189 
g/cm2 and 0.977 (0.115) g/cm2 and total hip BMD was 0.836 (0.118) g/cm2 and 0.849 (0.117) 190 
g/cm2 in the calcium treatment and control groups respectively. One study had loss to follow-191 
up of less than 5% (21), two between 5% and 20% (19, 22), one of 30% (23), and loss to follow-192 
up was unclear in the remaining one study (20). None of the studies addressed missing data, 193 






Assessment of risk of bias 196 
Overall, assessment of risk of bias suggested a high risk of bias in all included studies 197 
(Supplementary Figure 1). Adequate description of randomization was given in one study(19), 198 
and the remaining four reported randomized allocation but without describing randomization 199 
procedures. Allocation concealment was not clearly stated in three placebo-controlled studies 200 
(20-22) and was inadequate in the remaining two studies with no intervention as controls (19, 201 
23). Of the three placebo-controlled trials, two used a double-blinding design (21, 22) while 202 
the other one did not state the blinding strategy (20). How missing data were handled in two 203 
studies (20, 23) was not well described, indicating a potential attrition bias. No trials were 204 
registered online or provided a study protocol (four completed before 2000 and one in 2011), 205 
suggesting the potential for reporting bias. 206 
 207 
Effects of calcium supplementation on BMD 208 
For change in BMD from baseline to the end of calcium supplementation in each study, the 209 
pooled results for lumbar spine (5 studies: 275 participants in calcium and 252 in control arms) 210 
and forearm (4 studies: 217 participants in calcium and 198 in control arms) BMD are shown 211 
in Figure 2 and Table 2. Compared to placebo, calcium supplementation did not significantly 212 
reduce the loss of BMD at the lumbar spine (WMD 0.74% [95% CI -0.10, 1.59]; p = 0.09, I2 = 213 
47% [95% CI 0, 81]) or the forearm (WMD 0.53% [95% CI -0.35, 1.42], p = 0.24, I2 = 55% 214 
[95% CI 0, 85]). Table 2 also provides the effect estimates from single studies for BMD of the 215 
total body (21), total hip (23) and femoral neck (20). Compared to placebo, calcium 216 
supplementation increased BMD of the total hip (WMD 3.30% [95% CI 1.53, 5.07]; p < 0.001) 217 
but not the total body or femoral neck. However, the single study reporting total hip BMD (23) 218 





calcium supplementation mostly after the cessation of lactating (see also below sensitivity 220 
analysis).  221 
Three- and six-month changes in BMD were reported in 3 studies for lumbar spine and 2 studies 222 
for forearm (Figure 3). Overall, calcium supplementation reduced the loss of BMD at the 223 
lumbar spine over 3 and 6 months and the forearm over 6 months, although these findings were 224 
primarily driven by one large, heavily weighted study (19). 225 
We downgraded the quality of evidence by three levels for high risk of bias, inconsistency, 226 
imprecision, indirectness and/or publication bias for all BMD outcomes, resulting in a GRADE 227 
assessment of very low certainty of the evidence for all BMD outcomes. 228 
 229 
Sensitivity analysis 230 
All included studies did not perform or state allocation concealment adequately. Therefore, no 231 
sensitivity analysis was performed by omitting studies with inappropriate or unclear allocation 232 
concealment. After excluding two studies that used no intervention as control group, calcium 233 
supplementation showed no or small effect on lumbar spine BMD (WMD 0.91% [95% CI -234 
0.06, 1.87]; p = 0.07, I2 = 0% [95% CI 0, 85]) or forearm (WMD 1.01% [95% CI -0.003, 2.03]; 235 
p = 0.05, I2 = 10% [95% CI 0, 86]), n=181 from 3 studies (20-22).  236 
One study (23) was markedly different from the remaining studies in that breastfeeding was of 237 
short duration (and in fact the bulk of supplementation was given after breastfeeding ceased), 238 
calcium supplement dose was low and supplementation commenced late (3 months postpartum 239 
rather than 2 weeks or less) and participants were Chinese rather than all or predominantly 240 
white. Furthermore, this study was the only study in which lumbar spine BMD increased over 241 





post hoc sensitivity analysis. In addition, change in BMD over 6 months from one study was 243 
used in this post hoc sensitivity analysis as in this study that was the point at which 244 
breastfeeding ceased (19). In this sensitivity analysis, the effect of calcium supplementation 245 
and statistical heterogeneity were both markedly reduced for lumbar spine BMD (4 studies, 246 
455 participants, WMD 0.40% [95% CI 0.32, 0.49]; p < 0.001, I2 = 0 [95% CI 0, 79]) and were 247 
not materially changed for forearm BMD (4 studies, 455 participants, WMD 0.54% [95% CI -248 
0.18, 1.26]; p=0.14, I2 = 41% [95% CI 0, 80]). Another sensitivity analysis excluding a study 249 
that was published only as a conference abstract(20) did not materially affect the results (BMD 250 
of the lumbar spine (4 studies, 448 participants, WMD 0.67% [95% CI -0.37, 1.72]; p=0.21, I2 251 
= 46% [95% CI 0, 82]) and forearm (3 studies, 336 participants, WMD 0.59% [95% CI -0.73, 252 
1.90]; p=0.38, I2 = 61% [95% CI 0, 89])). 253 
 254 
Publication bias 255 
Visual inspection of the funnel plots for lumbar spine BMD did not suggest publication bias, 256 
but there was possible asymmetry for forearm BMD such that publication bias could not be 257 
ruled out (Supplementary Figure 2).  258 
 259 
Discussion 260 
To the best of our knowledge, this is the first systematic review and meta-analysis to evaluate 261 
the effect of calcium supplementation on BMD in lactating women. At best, calcium 262 
supplementation of 600-1000 mg/day in lactating women resulted in only a small and 263 
statistically non-significant benefit for BMD of the lumbar spine (WMD 0.74% [95% CI -0.10, 264 
1.59]) and the forearm (WMD 0.53% [95% CI -0.35, 1.42]) that was unlikely to be clinically 265 





is assessed as very low. The effect of calcium supplementation on change in BMD over 3 and 267 
6 months was primarily driven by the Polatti study (19) because of its larger sample size and 268 
greater precision of BMD measurement, but this study did not report baseline calcium intake. 269 
Nonetheless, the pooled results were not materially changed after excluding the Polatti study 270 
(19) and another study (23) with no intervention as control group. Evidence for effects at other 271 
sites was sparse. BMD at each of total body, total hip and femoral neck was only assessed in 272 
single studies. These reported no effects at those sites except for a 3.30% difference in change 273 
in total hip BMD in a single study (23), but it is important to note that this study (23) had 274 
different design that mainly focused on the effect of calcium supplementation during post-275 
weaning period, making the results less comparable to those in other studies. Nevertheless, this 276 
study would suggest that calcium supplement may improve BMD recovery after lactation, and 277 
this type of design may be important to consider in future studies. 278 
Irrespective of the poor quality of the evidence, the effect sizes for BMD at the lumbar spine, 279 
forearm, total body and femoral neck (0.33% to 1.10%) are too small to be clinically 280 
meaningful. In older people, a 10% higher BMD of the lumbar spine and femoral neck is 281 
associated with approximately 50% reduction in long-term fracture risk (33), and the effect 282 
sizes of our study are therefore unlikely to be translated into a noteworthy reduction in fracture 283 
risk. Moreover, there is no evidence that a history of lactation is associated with increased 284 
fracture risk in later life (34), so the likelihood of reducing fractures in later life through this 285 
strategy would seem low. Postpartum osteoporosis and fractures are rare and have only been 286 
described in a few case reports (35). Although bone loss during lactation may cause an 287 
increased risk of osteoporosis and fractures, Kovacs has proposed this may only be a 288 
coincidental condition caused by pre-existing low bone density for the majority of women (36) 289 
and our review suggests that it is unlikely that calcium supplementation during lactation would 290 





While calcium supplementation showed a moderate effect on total hip BMD, this was based 292 
on a single study with high risk of bias and in which calcium supplementation began 3 months 293 
after birth and presumably the establishment of breastfeeding, and given that the mean duration 294 
of breastfeeding tanged from 80 to 120 days, supplementation was primarily administered after 295 
breastfeeding ceased and recovery of bone mass commenced (23). This is consistent with the 296 
fact that in this study BMD increased rather than decreased in both intervention groups. The 297 
effect on the total hip in this study of 3.3% over 9 months is closer to being clinically important 298 
and this raises the question of whether calcium supplementation on cessation of rather than 299 
during breastfeeding could be beneficial. However, more evidence from high-quality RCTs is 300 
needed to address this question.  301 
There were insufficient studies in this review to allow for a meaningful subgroup analysis by 302 
baseline calcium intake. In only two trials was the average baseline calcium intake lower than 303 
the recommended intake of 1000 mg/day for lactating women aged 18 or older (being 562 and 304 
614 mg/day) (22, 23). The possibility of a BMD effect occurring in women with very low 305 
calcium intake cannot be ruled out and such women could be the target population in any future 306 
clinical trials. RCTs in women with low calcium intake may also provide additional evidence 307 
to support the setting of recommended dietary calcium intakes in lactating adults. Of note, a 308 
higher intake is recommended for lactating women aged 18 or younger (1300 mg/day) (17), 309 
but no trials have examined the effect of calcium supplementation in this age group. Therefore, 310 
this recommendation may also be warranted unless new evidence becomes available.  311 
Strengths and limitations of the study 312 
This systematic review was conducted following a prespecified, registered protocol using 313 
Cochrane methodology. We performed a comprehensive search of multiple databases and 314 
clinical trial registries without restricting language or publication status of the trials. It is 315 





The most important limitation of this review comes from the five included trials themselves. 317 
All included trials had a high risk of bias, and we have downgraded the quality of evidence to 318 
very low for all findings. The possibility of confounding cannot be ruled out because four out 319 
of the five trials included did not provide detailed information about the randomization process.  320 
However, effect sizes in this review were small and of doubtful clinical importance, and given 321 
the known tendency of trials with higher risk of bias to overestimate treatment effects (37, 38), 322 
it seems likely that the robust clinical trials required to definitively confirm this lack of effect 323 
should not be a high research priority. We included two trials using no intervention as control 324 
group due to the limited number of placebo-controlled trials based on the pre-specified protocol, 325 
but the main outcome of BMD was measured by DXA which is unlikely to be influenced by 326 
the knowledge of grouping. The exclusion of these two trials in a sensitivity analysis did not 327 
significantly change the pooled results, suggesting no impact of this issue on our conclusions. 328 
The limited number of studies precluded using subgroup analyses to explore the moderate 329 
statistical heterogeneity observed and assess potential effect modification. Instead, we 330 
addressed heterogeneity by excluding a study with markedly different characteristics of study 331 
design and population (23). The results of this analysis of the remaining four studies showed 332 
only a very small effect of calcium supplementation on lumbar spine BMD. Therefore, it may 333 
be that the main pooled result overestimates the effect of calcium supplementation in lactating 334 
women and should be interpreted with caution.  335 
 336 
Conclusion 337 
Overall, the meta-analysis indicates that calcium supplementation does not provide clinically 338 
important benefits for BMD in lactating women. However, the mean dietary intake was 339 
adequate before supplementation in some studies, and others did not measure baseline dietary 340 





(including with supplements if dietary intake is low and cannot otherwise be increased) is 342 
warranted unless new high certainty evidence to the contrary from robust clinical trials 343 
becomes available. More research needs to be done in larger samples of women from diverse 344 
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Table 1. Characteristics of included studies 
BMD, bone mineral density; Ca, calcium; DXA, dual-energy x-ray absorptiometry; NS, not stated; SD, standard deviation. 
1 Ca intake in the placebo group at 12 weeks lactation; baseline calcium intake was unavailable. 
2 Median (Interquartile range). 
3 Lactation occurred for a month or less of the supplementation period. 
4 Polatti 1999 and Yu 2011 did not have placebo group and used no intervention as control group.
Study No.  Ca/Control 
Age, years  















Start Duration  Baseline End points Time interval 
Cross 1995 
(21) 7/8 28.2 (1.3) White 1333 (86) 7.6 months 1000 400 IU/day 
< 2 weeks 
postpartum 10 months 
 < 2 weeks 
postpartum 
3 months lactation; 
3 months 
postweaning 
10 months DXA 
Whole-body, lumbar spine, 
radius (proximal 1/3, mid- and 
ultradistal) 
Kent 1995 
(20) 44/35 31 (NS) White 1056 (284) 
1 6 months 1000 No 36 weeks pregnancy 7 months 
 1 week 
postpartum 24 weeks lactation 6 months DXA 
Lumbar spine, proximal femur 
(neck, trochanteric and 
intertrochanteric), radius and 
lower limb (shaft and 
ultradistal) 
Kalkwarfa 
1997 (22) 45/42 30 (3) 84% white 614 (472 to 753) 
2 6 months 1000 400 IU/day 16 ± 2 days postpartum 6 months 
 16 ± 2 days 
postpartum 
3 and 6 months 
after enrolment 6 months DXA 
Lumbar spine, 
radius (shaft and ultradistal) 
Polatti 1999 
(19) 139/135 29.5 (3.0) White NS 6 months 1000 No 
5-10 days 
postpartum 18 months 
 5-10 days 
postpartum 
3, 6, 7, 12 and 18 
months postpartum 18 months DXA 
Lumbar spine,  
radius (distance to ulna < 
8mm) 









 Table 2. Summary of findings of eligible randomized controlled trials (n=5) evaluating the effect of calcium supplementation for improving bone mineral density in 
lactating women. 
Sites of BMD measures 





supplementation Difference (95% CI) (GRADE) 
Lumbar spine  
Follow up: 6 to 18 months 






0.74 (95% CI -0.10, 
1.59; p=0.09)  
⊕⊝⊝⊝ 
VERY LOW (Risk of 
bias, inconsistency and 
indirectness) 1 
Calcium supplementation may have no effect for 
preventing the loss of lumbar spine BMD 
Forearm 
Follow up: 6 to 18 months 






0.53% (95% CI -0.35, 
1.42; p=0.24) 
⊕⊝⊝⊝ 
VERY LOW (Risk of 
bias, inconsistency and 
publication bias) 2 
Calcium supplementation may have no effect on 
the loss of forearm BMD 
Total body BMD 
Follow up: 10 months 





1.03% (95% CI -0.75, 
2.81; p=0.26) 
⊕⊝⊝⊝ 
VERY LOW (Risk of bias 
and imprecision) 3 
Calcium supplementation appears to not reduce 
the loss of whole-body BMD 
Total hip BMD 
Follow up: 9 months 





3.30% (95% CI 1.53, 
5.07; p<0.001) 
⊕⊝⊝⊝ 
VERY LOW (Risk of 
bias, indirectness and 
imprecision) 4 
Calcium supplementation may have a moderate 
effect for reducing the loss of total hip BMD 
Femoral neck BMD 
Follow up: 6 months 





1.10% (95% CI -0.43, 
2.63; p=0.16) 
⊕⊝⊝⊝ 
VERY LOW (Risk of bias 
and imprecision) 5 
Calcium supplementation may have little or no 
effect on the loss of femoral neck BMD 
BMD: Bone mineral density; CI: Confidence interval; RCT: Randomized controlled trial. 
1 Risk of bias: inadequate random sequence generation, and inadequate or lack of concealment of allocation, resulting in potential selection bias; inadequate or lack of blinding of 
participants and personnel resulting in potential performance bias; inadequate description of missing data resulting in potential attrition bias. Inconsistency: Yu 2011 (23) observed a 
significantly larger effect of calcium supplementation compared to other trials and used no intervention as control, and Polatti 1999 (19) used no intervention as control and had a 
remarkably smaller variation of change in BMD than other studies. Indirectness: Yu 2011 (23) mainly targeted on the effect of calcium supplementation on BMD in post-lactating 
rather than lactating women. 
2 Risk of bias: inadequate random sequence generation and concealment of allocation resulting in potential selection bias; inadequate or lack of blinding of participants and personnel 
resulting in potential performance bias; inadequate description of missing data resulting in potential attrition bias. Inconsistency: Polatti 1999 (19) used no intervention as control and 
had a remarkably smaller variation of change in BMD than other studies. Publication bias: funnel plot indicates a potential publication bias.  
3 Risk of bias: inadequate random sequence generation and concealment of allocation resulting in potential selection bias; inadequate blinding of participants and personnel resulting in 
potential performance bias. Imprecision: only one study (21) with a very small sample size was available, and the wide confidence interval may influence clinical decision. 
4 Risk of bias: inadequate random sequence generation and concealment of allocation, resulting in potential selection bias; lack of blinding of participants and personnel (no 
intervention as control) resulting in potential performance bias; inadequate description of a high proportion of missing data (30%) may lead to potential attrition bias. Indirectness: Yu 
2011 (23) mainly targeted on the effect of calcium supplementation on BMD in post-lactating rather than lactating women. Imprecision: only one study was available, and the wide 
confidence interval may influence clinical decision. 
5 Risk of bias: inadequate random sequence generation and concealment of allocation, resulting in potential selection bias; inadequate blinding of participants and personnel resulting in 
potential performance bias; inadequate description of missing data resulting in potential attrition bias; trial was published as a conference abstract with many details of the study 






Figure 1. Flow chart of the study. 1 All records from ClinicalTrials.gov and WHO trials portal 
were assessed and excluded. 
Figure 2. Random effects meta-analysis of effect of calcium supplementation on percentage 
change in BMD of the lumbar spine and forearm from baseline to the end of supplementation. 
Figure 3. Random effects meta-analysis of effect of calcium supplementation on percentage 
change in BMD of the lumbar spine and forearm from baseline to 3 or 6 months. 
